This Dividend Blue Chip is a Classic Buffett Style 'Fat Pitch'

This Dividend Blue Chip is a Classic Buffett Style ‘Fat Pitch’

Posted On November 24, 2020 3:45 am
By: Dividend Sensei

This blue-chip is one of the most successful pharma giants when it comes to sales and cash flow-boosting mergers and acquisitions. This company hasn’t cut it since at least 1985, and it’s working with a 13-year growth streak right now. It’s risk-adjusted expected returns are more than 7X that of the S&P 500. If it grows at the 6% to 12% CAGR that analysts expect there’s a 90% probability it will deliver market-beating returns over the next decade.

Continue Reading Here

About author

Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.